OncoMed Pharma (OMED) Tops Q1 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. LEVI
2. NVDA
3. SPY
4. GOOGL
5. APLD
6. STZ
7. AGNT
8. ORCL
9. MSFT
10. SPCX

Go back to OncoMed Pharma (OMED) Tops Q1 EPS by 2c

OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results

May 8, 2017 6:50 AM EDT

Q1 Cash Balance of $156.9M Cash Through Q3 2019

Phase 2 Demcizumab DENALI Non-Small Cell Lung Cancer Trial Did Not Meet Endpoints

Focused on Immuno-Oncology Pipeline and Celgene Collaboration Programs

Management to Host Conference Call/Webcast this Morning at 8:30 a.m. ET / 5:30 a.m. PT

REDWOOD CITY, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced first quarter financial results.  As of March 31, 2017, cash, and short-term... More